Search Results - "WICKMAN, Grant R"

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 by HU-LOWE, Dana D, ZOU, Helen Y, MCTIGUE, Michele A, MURRAY, Brion W, KANIA, Robert S, O'CONNOR, Patrick, SHALINSKY, David R, BENDER, Steve L, GRAZZINI, Maren L, HALLIN, Max E, WICKMAN, Grant R, AMUNDSON, Karin, CHEN, Jeffrey H, REWOLINSKI, David A, YAMAZAKI, Shinji, WU, Ellen Y

“…Purpose: Axitinib (AG-013736) is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in…”
Get full text

Defective apoptotic cell contractility provokes sterile inflammation, leading to liver damage and tumour suppression by Julian, Linda, Naylor, Gregory, Wickman, Grant R, Rath, Nicola, Castino, Giovanni, Stevenson, David, Bryson, Sheila, Munro, June, McGarry, Lynn, Mullin, Margaret, Rice, Alistair, Del Río Hernández, Armandodel, Olson, Michael F

“…Apoptosis is characterized by profound morphological changes, but their physiological purpose is unknown. To characterize the role of apoptotic cell…”
Get full text

Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers by Hamblett, Kevin J., Hammond, Phil W., Barnscher, Stuart D., Fung, Vincent K., Davies, Rupert H., Wickman, Grant R., Hernandez, Andrea, Ding, Tong, Galey, Adam S., Winters, Geoffrey C., Rich, Jamie R., Babcook, John S.

“…Abstract Therapies targeting HER2 have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Unfortunately, many patients…”
Get full text

Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window by Davies, Rupert H., Barnscher, Stuart D., Chan, Peter W., Madera, Laurence, Rich, Jamie R., Vallejo, Marylou, Wickman, Grant R., Yin, Kevin, Fung, Vincent, Hamblett, Kevin J., Kaminker, Patrick G., Babcook, John S.

“…Abstract Antibody drug conjugate (ADC) therapies such as Kadcyla® and Adcetris® have significantly improved outcomes for patients. Despite these early…”
Get full text